SC
CRL icon

Savant Capital’s Charles River Laboratories CRL Stock Holding History

Savant Capital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$776K Buy
+3,335
New +$594K ﹤0.01% 1000

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Savant Capital's CRL Position: Q2 2026 in Review

Savant Capital opened a new position in Charles River Laboratories (CRL) in Q2 2026: 3,335 shares worth $776K. The stake represents ﹤0.01% of the portfolio and ranks #1000 among its holdings.

565 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Savant Capital held 3,335 shares of Charles River Laboratories worth $776K as of Q2 2026.
  • Charles River Laboratories was a new Savant Capital position in Q2 2026.
  • Charles River Laboratories made up ﹤0.01% of Savant Capital's portfolio in Q2 2026, its #1000 holding.
  • 565 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Savant Capital's 13F filing for Q2 2026, filed 10 Aug 2026.